Clinical Trials Logo
  1. Home
  2. Bladder Cancer
  3. NCT05195515
  4. Details
NCT05195515 Clinical Trial

The Impact of Late Effects After Treatment for Bladder Cancer on Quality of Life

Bladder Cancer Clinical Trial

— CONQUER  

Official title:
The Impact of Late Effects After Treatment for Bladder Cancer on Quality of Life - What is the Cost of the Cure?

Clinical Trial Details — Status: Enrolling by invitation

Administrative data
NCT number NCT05195515
Other study ID # CONQUER
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date January 1, 2022
Est. completion date December 31, 2027

Study information
Verified date July 2023
Source Aarhus University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Bladder Cancer prognosis, treatment, and subsequent morbidity and mortality vary between the different stages, thus resulting in a different impact on patients' lives. There are some well known late effects of the treatments for bladder cancer, but the knowledge of their impact on patients Quality of Life is sparse. This study aims to determine the prevalence of late effects impact on Quality of Life and potential risk factors for impairment.

Recruitment information / eligibility
Status Enrolling by invitation
Enrollment 2000
Est. completion date December 31, 2027
Est. primary completion date December 31, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients are eligible if they are referred to a hospital in the Central Region Denmark, due to hematuria between 01/01/2022 and 01/01/2023 - Ability to understand written and oral Danish Exclusion Criteria: - Known Alzheimers disease - Diagnosed other causes explaining the hematuria

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Denmark Department of Urology, Aarhus University Hospital Aarhus N
Denmark Department of Urology, Regional Hospital Gødstrup Gødstrup
Denmark Department of Urology, Regional Hospital Horsens Horsens
Denmark Department of Urology, Regional Hospital Randers Randers
Denmark Department of Urology, Regional Hospital Viborg Viborg

Sponsors (3)
Lead Sponsor Collaborator
Aarhus University Hospital Aarhus University, Institute of Clinical Medicine, National Research Center for Survivorship and Late Adverse Effects Following Pelvic Organ Cancer, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome
Type Measure Description Time frame Safety issue
Primary Health-related Quality of Life Changes in Quality of Life measured using validated instruments 5 years from baseline inclusion
Secondary Prevalence of late effects Based on Patient Reported Outcomes and medical records 5 years from baseline inclusion
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06034015 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers Phase 1
Recruiting NCT04235764 - En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Completed NCT02371447 - VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04081246 - Transurethral Modified En Bloc Resection For Large Bladder Tumours. N/A
Recruiting NCT06059547 - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Phase 2
Terminated NCT04779489 - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer N/A
Not yet recruiting NCT04493489 - Propranolol Adjuvant Treatment of Bladder Cancer Phase 2
Completed NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT04537221 - Nordic Cystectomy Study III - Transfusion
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05562791 - A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer Phase 1
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT02781428 - To Detect the Sensitivity of the UroMark Assay
Recruiting NCT04738630 - Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Phase 2
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03978624 - Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Phase 2
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A